SEC Company Response from Protalix BioTherapeutics, Inc. (PLX) (CIK 0001006281) (PLX) — Sep 25, 2007
Protalix BioTherapeutics, Inc. (PLX) (CIK 0001006281)
Date: Sept. 25, 2007 · CIK: 0001006281 · Accession: 0000950136-07-006640
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-144801
Letter
Protalix BioTherapeutics, Inc.
2 Snunit Street
Science Park
Carmiel 20100
Israel
September 25, 2007
VIA COURIER AND EDGAR
Mr. Greg Belliston
Securities and Exchange Commission
Division of Corporate Finance
Mail Stop 6010
100 F Street, N.E.
Washington, D.C. 20549
Re:
Protalix BioTherapeutics, Inc.
Registration Statement on Form S-3 (File No. 333-144801)
Acceleration Request
Ladies and Gentlemen:
Protalix BioTherapeutics, Inc. (the “Company”) pursuant to Rule 461 under the Securities Act of 1933, as amended, hereby requests the Securities and Exchange Commission (the “Commission”) to accelerate the effective date of the above-referenced Registration Statement and declare the Registration Statement, as then amended, effective as of 4:30 P.M., eastern standard time, on September 26, 2007, or as soon thereafter as practicable. The Company also requests the Commission to specifically confirm such effective date and time to the Company in writing.
The Company acknowledges that (i) should the Commission or the staff of the Commission, acting pursuant to delegated authority, declare the filing effective, such declaration does not foreclose the Commission from taking any action with respect to the filing; (ii) the action of the Commission or the staff of the Commission, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and (iii) the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Please contact Jim Tanenbaum of Morrison & Foerster LLP with any questions or comments at 212-468-8163. Thank you for your assistance with this filing.
Sincerely yours,
PROTALIX BIOTHERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm Protalix BioTherapeutics, Inc. 2 Snunit Street Science Park Carmiel 20100 Israel September 25, 2007 VIA COURIER AND EDGAR Mr. Greg Belliston Securities and Exchange Commission Division of Corporate Finance Mail Stop 6010 100 F Street, N.E. Washington, D.C. 20549 Re: Protalix BioTherapeutics, Inc. Registration Statement on Form S-3 (File No. 333-144801) Acceleration Request Ladies and Gentlemen: Protalix BioTherapeutics, Inc. (the “Company”) pursuant to Rule 461 under the Securities Act of 1933, as amended, hereby requests the Securities and Exchange Commission (the “Commission”) to accelerate the effective date of the above-referenced Registration Statement and declare the Registration Statement, as then amended, effective as of 4:30 P.M., eastern standard time, on September 26, 2007, or as soon thereafter as practicable. The Company also requests the Commission to specifically confirm such effective date and time to the Company in writing. The Company acknowledges that (i) should the Commission or the staff of the Commission, acting pursuant to delegated authority, declare the filing effective, such declaration does not foreclose the Commission from taking any action with respect to the filing; (ii) the action of the Commission or the staff of the Commission, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and (iii) the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. Please contact Jim Tanenbaum of Morrison & Foerster LLP with any questions or comments at 212-468-8163. Thank you for your assistance with this filing. Sincerely yours, PROTALIX BIOTHERAPEUTICS, INC. By: /s/ David Aviezer Name: David Aviezer Title: President and Chief Executive Officer cc: Morrison & Foerster LLP 2